# A Study Comparing the Efficacy and Safety Between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients

> **NCT02867566** · PHASE3 · COMPLETED · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 420 (actual)

## Conditions studied

- Diffuse, Large B-Cell, Lymphoma

## Interventions

- **DRUG:** IBI301 plus CHOP
- **DRUG:** Rituximab plus CHOP

## Key facts

- **NCT ID:** NCT02867566
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08-22
- **Primary completion:** 2019-09-05
- **Final completion:** 2019-12-26
- **Target enrollment:** 420 (ACTUAL)
- **Last updated:** 2020-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02867566

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02867566, "A Study Comparing the Efficacy and Safety Between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02867566. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*